4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening

Rezultaty

recruitment: description target population/ area

Description of dominant MPSG in high risk areas (that tend to elect not to participate but which are at high risk), and of MPSG for optimisation in those who tend to participate (M6)

Biomarkers: Validation circulating miRNA

Validation of two different computational models of circulating miRNAs to maximize sensitivity for risk prediction and specificity for differential diagnosis

Project Management: informed consent form

- The informed consent procedures that will be implemented for the participation of humans will be explained into detail. - providing templates of the informed consent form (per country)

Biomarkers: composite risk predicting panel

Combination of miRNAs, inflammatory proteins and cardio-pulmonary damage in a composite risk predicting panel.

recruitment: development tailored recruitment

Identification of the preferred per country and most effective channels of communication and development of the tailored intervention, with different MPSG profiles, at high risk of developing lung cancer, including qualitative data on the participants’ view of the methods

Protocol: study protocol 4-IN-THE-LUNG-RUN

Design of the study protocol

Data protection: security

A description of the security measures that will be implemented to prevent unauthorised access to personal data or the equipment used for processing

Protocol: Nodule Management Strategy

design of the lung cancer nodule management protocol

Approval: study protocol - registration

i Final version of study protocol as submitted to regulatorsethics committees ii Registration number of clinical study in a WHOor ICMJE approved registry with the possibility to post resultsiii Approvals ethics committees and national competent authority if applicable required for invitationenrolment of first subject in at least one clinical centre

Data protection: privacy - anonymised/ pseudomysed data

explain why the research data will not be anonymised/ pseudonymised

Publikacje

Personalising lung cancer screening: An overview of risk‐stratification opportunities and challenges

Autorzy: Kevin Haaf, Carlijn M. Aalst, Harry J. Koning, Rudolf Kaaks, Martin C. Tammemägi
Opublikowane w: International Journal of Cancer, Numer 149/2, 2021, Strona(/y) 250-263, ISSN 0020-7136
Wydawca: John Wiley & Sons Inc.
DOI: 10.1002/ijc.33578

Implementation of lung cancer screening: what are the main issues?

Autorzy: Carlijn M. van der Aalst, Kevin ten Haaf, Harry J. de Koning
Opublikowane w: Translational Lung Cancer Research, Numer 10/2, 2021, Strona(/y) 1050-1063, ISSN 2218-6751
Wydawca: AME Publishing Company
DOI: 10.21037/tlcr-20-985

P1.15-03 Dedicated Cardiovascular Screening in Lung Cancer Screening: Preliminary Results from the European 4-IN-THE-LUNG-RUN Trial,

Autorzy: M. Vonder, C. van der Aalst, J. Hubert, D. Moldovanu, A. Schmitz, J.W.C. Gratama, M. Silva, H. de Koning, M. Oudkerk
Opublikowane w: Journal of Thoracic Oncology, Numer Volume 18, Numer 11, Supplement, 2023, 2023, Strona(/y) Pages S218-S219, ISSN 1556-0864
Wydawca: Lippincott Williams & Wilkins Ltd.
DOI: 10.1016/j.jtho.2023.09.355

Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the Netherlands

Autorzy: Koen de Nijs, Kevin ten Haaf, Carlijn van der Aalst, and Harry J. de Koning
Opublikowane w: eClinical Medicine, Numer 2024; 102570, 2024, Strona(/y) 102570, ISSN 2589-5370
Wydawca: Elsevier BV
DOI: 10.1016/j.eclinm.2024.102570

Cardiovascular Screening In Lung Cancer Screening: The European Prospective Approach 4-in-the-lung-run

Autorzy: M. Vonder, C. van der Aalst, D. Moldovanu, J. Hubert, A. Schmitz, J. Gratama, M. Silva, H. de Koning, M. Oudkerk
Opublikowane w: Journal of Cardiovascular Computed Tomography, Numer Volume 17, Numer 4, Supplement, 2023, Strona(/y) S46, ISSN 1934-5925
Wydawca: Elsevier BV
DOI: 10.1016/j.jcct.2023.05.116

Lung cancer screening and smoking cessation efforts

Autorzy: Dana Moldovanu, Harry J. de Koning, Carlijn M. van der Aalst
Opublikowane w: Translational Lung Cancer Research, Numer 10/2, 2021, Strona(/y) 1099-1109, ISSN 2218-6751
Wydawca: AME Publishing Company
DOI: 10.21037/tlcr-20-899

P1.14-04 European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial

Autorzy: C. van der Aalst, M. Vonder, J. Hubert, D. Moldovanu, A. Schmitz, S. Delorme, R. Kaaks, K. ten Haaf , M. Oudkerk, H. de Koning
Opublikowane w: Journal of Thoracic Oncology, Numer Volume 18, Numer 11, Supplement, November 2023, 2023, Strona(/y) Page S217, ISSN 1556-1380
Wydawca: Elsevier
DOI: 10.1016/j.jtho.2023.09.352

MA19.06 Artificial Intelligence as Concurrent Reader in Prospective European Lung Cancer Screening (4-IN-THE-LUNG-RUN) Trial

Autorzy: M. Vonder, C. van der Aalst, J. Hubert, D. Moldovanu, A. Schmitz, S. Delorme, J.W. Gratama, M. Silva, H. de Koning, M. Oudkerk
Opublikowane w: Journal of Thoracic Oncology, Numer Volume 18, Numer 11, Supplement, November 2023, 2023, Strona(/y) Page S172, ISSN 1556-1380
Wydawca: Elsevier
DOI: 10.1016/j.jtho.2023.09.256

Rezultaty

Publikacje

Udostępnij tę stronę

Pobierz